<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Biomedical Journal</title>
<title_fa>مجله بیومدیکال ایران</title_fa>
<short_title>IBJ</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ibj.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>1028-852X</journal_id_issn>
<journal_id_issn_online>2008-823X</journal_id_issn_online>
<journal_id_pii>-</journal_id_pii>
<journal_id_doi>10.61882/ibj</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>-</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>-</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2021</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>25</volume>
<number>5</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Linagliptin Protects Human SH-SY5Y Neuroblastoma Cells against Amyloid-β Cytotoxicity via the Activation 
of Wnt1 and Suppression of IL-6 Release</title>
	<subject_fa>Tissue Engineering and Cell Biology</subject_fa>
	<subject>Tissue Engineering and Cell Biology</subject>
	<content_type_fa>مقاله کامل</content_type_fa>
	<content_type>Full Length/Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;strong&gt;Background: &lt;/strong&gt;Alzheimer&amp;rsquo;s disease is one of the neurodegenerative disorders typified by the aggregate of amyloid-&amp;beta; (A&amp;beta;) and phosphorylated tau protein. Oxidative stress and neuroinflammation, because of A&amp;beta; peptides, are strongly involved in the pathophysiology of Alzheimer&amp;rsquo;s disease (AD). Linagliptin shows neuroprotective properties against AD pathological processes through alleviation of neural inflammation and AMPK activation. &lt;strong&gt;Methods: &lt;/strong&gt;We assessed the benefits of linagliptin pretreatment (at 10, 20, and 50 nM concentrations), against A&amp;beta;1-42 toxicity (20 &amp;mu;M) in SH-SY5Y cells. The concentrations of secreted cytokines, such as TNF-&amp;alpha;, IL-6, and IL-1&amp;beta;, and signaling proteins, including pCREB, Wnt1, and PKC&amp;epsilon;, were quantified by ELISA. &lt;strong&gt;Results: &lt;/strong&gt;We observed that A&amp;beta; led to cellular inflammation, which was assessed by measuring inflammatory cytokines (TNF-&amp;alpha;, IL-1&amp;beta;, and IL-6). Moreover, A&amp;beta;1-42 treatment impaired pCREB, PKC&amp;epsilon;, and Wnt1 signaling in human SH-SY5Y neuroblastoma cells. Addition of Linagliptin significantly reduced IL-6 levels in the lysates of cells, treated with A&amp;beta;1-42. Furthermore, linagliptin prevented the downregulation of Wnt1 in A&amp;beta;1-42-treated cells exposed. &lt;strong&gt;Conclusion: &lt;/strong&gt;The current findings reveal that linagliptin alleviates A&amp;beta;1-42-induced inflammation in SH-SY5Y cells, probably through the suppression of IL-6 release, and some of its benefits are mediated through the activation of the Wnt1 signaling pathway.</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Alzheimer disease, Interleukin-6, Linagliptin, Wnt1 protein</keyword>
	<start_page>343</start_page>
	<end_page>348</end_page>
	<web_url>http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-4087-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Mohsen</first_name>
	<middle_name></middle_name>
	<last_name>Sedighi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>sedighi1984@yahoo.com</email>
	<code></code>
	<orcid>0000-0003-0608-7840</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Neuroscience Research Center, Iran University of Medical Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Tourandokht</first_name>
	<middle_name></middle_name>
	<last_name>Baluchnejadmojarad</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>moornani@gmail.com</email>
	<code></code>
	<orcid>0000-0002-2703-728X</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mehrdad</first_name>
	<middle_name></middle_name>
	<last_name>Roghani</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>bahman19832003@yahoo.com</email>
	<code></code>
	<orcid>0000-0002-9209-8484</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Neurophysiology Research Center, Shahed University, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
